Showing results (141-150 of 214) with videos related to
Sort By:
Pageof 22
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1996
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parametersV Mummaneni, S Kaul, L N Igwemezie, et al.Journal of Medicinal Chemistry|December 19, 1998
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)R J Griffin, S Srinivasan, K Bowman, et al.British Journal of Cancer|January 1, 1997
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell linesE J Estlin, K Balmanno, A H Calvert, et al.British Journal of Cancer|February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277B J Foster, D R Newell, J Carmichael, et al.Cancer Treatment Reports|August 1, 1986
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouseD R Newell, D L Alison, A H Calvert, et al.British Journal of Cancer|January 7, 2010
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapyJ E Nutt, A R A Razak, K O'Toole, et al.Cancer Chemotherapy and Pharmacology|January 1, 1997
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade gliomaM Bower, E S Newlands, N M Bleehen, et al.Journal of Medicinal Chemistry|March 1, 1989
Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 positionP R Marsham, P Chambers, A J Hayter, et al.European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancerM Gore, A Oza, G Rustin, et al.British Journal of Cancer|May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxelA N Hughes, M J Griffin, D R Newell, et al.Pageof 22